We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.57% | 14.50 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 1,101,026 | 10:04:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.74 | 37.78M |
TIDMAGL
Angle PLC
14 May 2018
For immediate release 14 May 2018
ANGLE plc ("the Company")
LEADING NHS PROSTATE CANCER SURGEON APPOINTED AS SCIENTIFIC ADVISOR
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Mr Greg L Shaw as a Scientific Advisor to the Company.
Joining the Company's already established Scientific Advisory Board, Mr Shaw brings significant additional prostate cancer and UK NHS clinical experience.
Mr Shaw is a Consultant Urological Surgeon at University College Hospital in London and is a clinical academic with a strong interest in prostate cancer diagnostics and treatment. Having completed an M.D. in prostate cancer at the University of London investigating circulating tumour cells in prostate cancer, and subsequently completed four years as a lecturer at the University of Cambridge, Mr Shaw has published widely on prostate cancer and is currently an honorary senior lecturer at University College and Queen Mary College of the University of London.
He leads several research programs focused on current weaknesses in the way prostate cancer is treated and is interested in exploring the role novel biomarkers may play in advancing practice in these areas.
Mr Shaw is currently chief investigator for two NIHR portfolio studies investigating 1) the effects of refinements to robotic surgery and 2) the use of drugs to prevent progression in men on active surveillance for prostate cancer respectively.
Mr Shaw is an expert in robotic surgery with a high case volume. He is known for his innovative approach and commitment to quality assurance.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"As we prepare to extend our prostate cancer work, we are delighted that we will be able to benefit from Greg Shaw's extensive experience in this area. Greg's understanding of current clinical practice in the UK and the key areas of medical need that liquid biopsy can address will help us to position Parsortix(TM) clinical applications for prostate cancer in the future."
Mr Greg Shaw, Consultant Urological Surgeon at University College Hospital, said:
"I am delighted to be joining ANGLE's Scientific Advisory Board. Having worked as a Consultant Urological Surgeon pursuing a specialist interest in prostate cancer over the last 14 years, I am encouraged by the development of the Parsortix system and the potential it holds for the diagnosis and assessment of prostate cancer. I look forward to helping the ANGLE team as they progress the development of prostate cancer clinical applications, using the Parsortix system."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain +44 (0)20 7220 0500 WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee +44 (0) 203 705 9330 FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000 Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM) system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of all types is called Ziplex(R) and is based on a patented flow through array technology. It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. These technologies can be combined to provide fully automated, sample to answer results in both centralised laboratory and point of use cartridge formats. It is ideal for measuring gene expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUORNRWOAVAAR
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions